Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with
its collaborators, will present data from more than 30 abstracts
showcasing the benefit of Adaptive’s next-generation sequencing
(NGS)-based clonoSEQ® Assay in measuring minimal residual disease
(MRD) in blood cancer patients at the 64th Annual Meeting of the
American Society of Hematology (ASH) taking place December 10-13,
2022.
clonoSEQ is the only U.S. Food and Drug Administration
(FDA)-cleared assay for MRD assessment in multiple myeloma (MM),
chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic
leukemia (B-ALL). Adaptive recently announced the launch of
clonoSEQ to assess MRD in the blood of patients with diffuse large
B-cell lymphoma (DLBCL) using ctDNA. The assay is widely available
to clinicians and patients across the U.S.
“The data presented at ASH continues to reinforce the value of
serial MRD testing with clonoSEQ as a sensitive prognostic tool in
real-world settings and in clinical trials,” said Nitin Sood, chief
commercial officer, MRD, Adaptive Biotechnologies. “Data continues
to demonstrate that testing MRD at multiple timepoints throughout a
patient’s cancer journey is part of the new standard of care for
most lymphoid malignancies and is critical to a physician’s ability
to assess prognosis, determine response to treatment, detect
relapse, and ultimately optimize care.”
MRD testing allows for direct measurement of the number of
cancer cells remaining in the body during and after treatment.
Leveraging Adaptive’s immune medicine platform, clonoSEQ can detect
one cancer cell among a million healthy cells. Assessment with
clonoSEQ provides a standardized, accurate, and sensitive
measurement of MRD.
Data generated using clonoSEQ across various blood cancers will
be featured in the selected 12 oral presentations and 21 posters
listed below at ASH. Five of the presentations are studies using
real-world evidence to demonstrate how serial clonoSEQ testing is
being utilized in the clinic to inform physician decisions across
indications and therapeutic regimens to guide personalized
treatment plans, including discontinuation of therapy. Other
presentations will highlight the value of utilizing clonoSEQ in
clinical trials to assess and predict the effectiveness of
investigational, novel therapeutics.
Abstract |
Title |
Presentation Timing |
Oral Presentations |
Multiple Myeloma |
158 |
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody,
Induces Durable Clinical and Molecular Responses for Patients with
Relapsed or Refractory Multiple Myeloma |
Saturday, December 10, 2022: 12:15 PM |
361 |
KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel
in Clinical High-Risk Multiple Myeloma Patients with Early Relapse
after Frontline Autologous Stem Cell Transplantation |
Saturday, December 10, 2022: 4:00 PM |
565 |
Final Results from the First-in-Human Phase 1/2 Study of Modakafusp
Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts)
with Relapsed/Refractory Multiple Myeloma (RRMM) |
Sunday, December 11, 2022: 12:00 PM |
868 |
Early and Sustained Undetectable Measurable Residual Disease (MRD)
after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple
Myeloma (MM) Patients in Karmma Achieving Prolonged Survival |
Monday, December 12, 2022: 3:30 PM |
870 |
Prospective Trial Using Multimodal Measurable Residual Disease
Negativity to Guide Discontinuation of Maintenance Therapy in
Multiple Myeloma (MRD2STOP) |
Monday, December 12, 2022: 4:00 PM |
Chronic Lymphocytic Leukemia |
93 |
Residual Disease Kinetics Among Patients with High-Risk Factors
Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax
(Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow
Study |
Saturday, December 10, 2022: 10:00 AM |
344 |
Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib,
Venetoclax, Obinutuzumab (AVO) in a Population of Previously
Untreated Patients with CLL Enriched for High-Risk Disease |
Saturday, December 10, 2022: 4:15 PM |
Acute Lymphoblastic Leukemia |
213 |
Ponatinib and Blinatumomab for Patients with Newly Diagnosed
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A
Subgroup Analysis from a Phase II Study |
Saturday, December 10, 2022: 2:30 PM |
720 |
Ultra-Sensitive Next-Generation Sequencing Establishes the
Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic
Leukemia Undergoing Hematopoietic Cell Transplantation |
Monday, December 12, 2022: 11:45 AM |
Mantle Cell Lymphoma |
73 |
Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with
Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle
Cell Lymphoma |
Saturday, December 10, 2022: 9:30 AM |
75 |
Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in
the Treatment of Patients with Relapsed or Refractory Mantle Cell
Lymphoma, Including Those with TP53 Mutated and Btki-Refractory
Disease: First Report of the Tarmac Study |
Saturday, December 10, 2022: 10:00 AM |
Follicular Lymphoma |
952 |
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide
(ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of
Safety, Efficacy, and Minimal Residual Disease |
Monday, December 12, 2022: 5:15 PM |
Poster Presentations |
Multiple Blood Cancers |
2275 |
Interim Update on the ‘Watch’ Registry, a Real-World Observational
Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
4816 |
Utility of High-Throughput Sequencing of Immunoglobulin Genes for
MRD in Lymphoid Malignancy in the Context of Current
Immunotherapeutics |
Monday, December 12, 2022: 6:00 PM-8:00 PM |
Acute Lymphoblastic Leukemia |
2729 |
A Phase II Study of the Sequential Combination of Low-Intensity
Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By
Blinatumomab and Ponatinib in Patients with Philadelphia
Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) |
Sunday, December 11, 2022, 6:00 PM-8:00 PM |
Diffuse Large B-Cell Lymphoma |
4251 |
Epcoritamab Monotherapy Provides Deep and Durable Responses
Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup
Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell
Lymphoma (LBCL) |
Monday, December 12, 2022: 6:00 PM-8:00 PM |
Mantle Cell Lymphoma |
2884 |
Acalabrutinib Plus Venetoclax and Rituximab in Patients with
Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and
Efficacy Analysis |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
4806 |
Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual
Disease (MRD) Analysis Is an Effective Surveillance Tool in
Patients with Mantle Cell Lymphoma |
Monday, December 12, 2022: 6:00 PM-8:00 PM |
Multiple Myeloma |
3218 |
A Real-World Study on the Feasibility of Minimal Residual Disease
Testing By Next-Generation Sequencing in Systemic Light-Chain
Amyloidosis |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
1934 |
Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib,
Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly
Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute
(LCI) |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
1930 |
Quadruplet Induction, Autologous Transplantation and Minimal
Residual Disease Adapted Consolidation and Treatment Cessation in
Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup
Analysis of the Master Trial |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
3237 |
Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly
Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib,
Lenalidomide and Dexamethasone (Dara-KRd) and Autologous
Transplantation: Extended Follow up of the Master Trial |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
3239 |
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide,
Dexamethasone, and Isatuximab in Newly Diagnosed,
Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
3314 |
KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel
in Patients with Clinical High-Risk Multiple Myeloma Due to
Inadequate Response to Frontline Autologous Stem Cell
Transplantation |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
3313 |
Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with
Relapsed and /or Refractory Multiple Myeloma |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
3354 |
Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell
Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse
after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
2030 |
Efficacy Outcomes and Characteristics of Patients with Multiple
Myeloma (MM) Who Achieved Sustained Minimal Residual Disease
Negativity after Treatment with Ciltacabtagene Autoleucel
(cilta-cel) in CARTITUDE-1 |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
3593 |
Induction Quadruplet Therapy and Minimal/Measurable Residual
Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed
Multiple Myeloma (NDMM): Results from an Academic-Community
Pathway |
Saturday, December 10, 2022, 5:30 PM-7:30 PM |
4466 |
Needle in a Haystack: A Pilot Study Combining Single-Cell
Multiomics with Clinical NGS-MRD Sequencing to Search for
Circulating Clonotypic Dedifferentiated Myeloma Cells |
Monday, December 12, 2022: 6:00 PM-8:00 PM |
4527 |
Humoral Immune Reconstitution Following Therapy with Daratumumab,
Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous
Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted
Treatment Cessation |
Monday, December 12, 2022: 6:00 PM-8:00 PM |
4553 |
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with
Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age
Subgroup Analysis |
Monday, December 12, 2022: 6:00 PM-8:00 PM |
4559 |
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus
Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible
Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated
Analysis of the Phase 3 Maia Study |
Monday, December 12, 2022: 6:00 PM-8:00 PM |
4561 |
Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP)
Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in
Transplant-Ineligible Patients with Newly Diagnosed Multiple
Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study |
Monday, December 12, 2022: 6:00 PM-8:00 PM |
The clonoSEQ Assay leverages Adaptive Biotechnologies’
proprietary immune medicine platform to identify and quantify
specific DNA sequences found in malignant cells, allowing
clinicians to assess and monitor MRD during and after treatment.
The assay provides standardized, accurate, and sensitive
measurement of MRD that allows physicians to predict patient
outcomes, assess response to therapy over time, monitor patients
during remission, and predict potential relapse. Clinical practice
guidelines in hematological malignancies recognize that MRD status
is a reliable indicator of clinical outcomes and response to
therapy, and clinical outcomes have been shown to be strongly
associated with MRD levels measured by the clonoSEQ Assay in
patients diagnosed with CLL, MM, ALL and DLBCL.
For important information about the FDA-cleared uses of
clonoSEQ, including the full intended use, limitations, and
detailed performance characteristics, please visit
www.clonoSEQ.com/technical-summary.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with
the Securities and Exchange Commission from time to time.
We caution you that forward-looking statements are based on a
combination of facts and factors currently known by us and our
projections of the future, about which we cannot be certain. As a
result, the forward-looking statements may not prove to be
accurate. The forward-looking statements in this press release
represent our views as of the date hereof. We undertake no
obligation to update any forward-looking statements for any reason,
except as required by law.